ILLUMINATION IN HUMAN AGING: SLEEP AND MOOD EFFECTS

描述(改编自调查人员摘要)：大多数美国老年人 受到轻度抑郁或睡眠障碍的困扰，这通常是 紧密地交织在一起。在AG12364的前5年，他们一直在 研究老年志愿者抑郁和失眠的病因。他们的 研究结果表明，人类的昼夜节律失调程度令人震惊 美国人老龄化，这可能是他们失眠和情绪低落的部分原因。 此外，他们的志愿者表现出令人惊讶的昼夜节律和临床表现。 对4天强光处理的反应，表明可能有光 抵抗。在这次更新中，他们将测试更长时间的4周亮光 在家里进行治疗，以确定志愿者的耐光性是否会老化 60-79年可以通过更长的疗程来克服。一百 将招募50名有严重抑郁症状的志愿者参加 由一周的安慰剂基线在半夜睡眠中终止的试验 剥夺，然后4周随机分配给10,000勒克斯白 淡或10勒克司的红光安慰剂。基线期间的阶段输入将决定 在随机确定是否最好在早上进行治疗之前， 中午，或者晚上。部分尿样中的6-硫氧基黑素将 基线结束时收集48小时，结束时收集48小时 随机治疗，以确定10,000勒克斯治疗是否成功 使不同步的昼夜节律调整正常化。的成功之路 降低GDS抑郁评分和减少睡眠主诉的治疗 将会被检查。

DESCRIPTION (adapted from investigator's abstract): Most older Americans are troubled by low-level depression or sleep disturbances, which are often intimately intertwined. In the first 5 years of AG12364, they have been examining the etiologies of depression and insomnia in aging volunteers. Their findings suggest an appalling degree of circadian malsynchronization among aging Americans, which possibly explains part of their insomnia and low mood. Further, their volunteers displayed surprisingly weak circadian and clinical responses to 4 days of bright light treatment, indicating possible light resistance. In this renewal, they will test more extended 4-week bright light treatments in the home, to determine if light resistance in volunteers ages 60-79 years can be overcome with a longer duration of treatment. One hundred fifty volunteers with significant depressive complaints will be recruited for a trial consisting of one-week placebo baseline terminating in a half-night sleep deprivation, followed by 4 weeks randomized assignment to 10,000 lux white light or 10 lux red light placebo. Phase-typing during baseline will determine before randomization whether treatment should best be given in the morning, mid-day, or evening. Fractional urine samples for 6-sulphatoxymelatonin will be collected for 48 hours at the end of baseline and for 48 hours at the end of the randomized treatment, to determine if 10,000 lux treatments successfully normalize malsynchronized circadian phase adjustments. The success of the treatment in lowering the GDS depression score and in reducing sleep complaints will be examined.